EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm

Yasuhiro Nagate, Aya Nakaya, Ren Kamimura, Yumiko Hirose, Satoshi Nojima, Jiro Fujita, Eiji Kiyohara, Hirohiko Shibayama

Internal Medicine · 01.09.2023 · 62 (17) · 2547-2551

DOI: 10.2169/internalmedicine.0318-22 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Internal Medicine, erschienen am 01.09.2023. Verfasst von Yasuhiro Nagate und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, National Hospital Organization Osaka National Hospital, Japan. Hauptthemen laut MEDLINE: Skin Neoplasms, Myeloproliferative Disorders, Neutropenia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An 84-year-old Japanese man was diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN). We administered combination therapy using venetoclax and azacytidine. We observed neutropenia (Grade 4), thrombocytopenia (Grade 2), and stomatitis (Grade 3). After six cycles of treatment, the BPDCN abnormal cells in the bone marrow specimen almost disappeared, and atypical cells were not detected in a skin biopsy. We propose venetoclax combined with azacytidine as a useful treatment approach in elderly patients, although clinicians should be mindful that therapeutic modifications may be essential to minimize and/or avoid adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Skin NeoplasmsMyeloproliferative DisordersNeutropeniaAgedMaleHumansAged, 80 and overAzacitidineDendritic CellsSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

azacytidineblastic plasmacytoid dendritic cell neoplasm (BPDCN)elderlyfirst-linevenetoclax

Substanzen

AzacitidinevenetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Hematology, National Hospital Organization Osaka National Hospital, Japan.
  • Department of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Japan.
  • Department of Pathology, Osaka University Graduate School of Medicine, Japan.
  • Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Japan.
  • Department of Dermatology, Osaka University Graduate School of Medicine, Japan.

Zitieren

APA

Nagate, Y., Nakaya, A., Kamimura, R., Hirose, Y., Nojima, S., Fujita, J., Kiyohara, E., & Shibayama, H. (2023). Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm. Internal Medicine, 62(17), 2547-2551. https://doi.org/10.2169/internalmedicine.0318-22

Vancouver

Nagate Y, Nakaya A, Kamimura R, Hirose Y, Nojima S, Fujita J, et al. Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm. Internal Medicine. 2023;62(17):2547-2551. doi:10.2169/internalmedicine.0318-22

BibTeX
@article{Nagate2023,
  author = {Nagate, Yasuhiro and Nakaya, Aya and Kamimura, Ren and Hirose, Yumiko and Nojima, Satoshi and Fujita, Jiro and Kiyohara, Eiji and Shibayama, Hirohiko},
  title = {Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm},
  journal = {Internal Medicine},
  year = {2023},
  volume = {62},
  number = {17},
  pages = {2547--2551},
  doi = {10.2169/internalmedicine.0318-22}
}
Kostenlos starten →